Recruiting
Phase 1

DMT

Sponsor:

Yale University

Code:

NCT04711915

Conditions

Major Depressive Disorder

Depression

Eligibility Criteria

Sex: All

Age: 21 - 65

Healthy Volunteers: Accepted

Interventions

0.1 mg/kg Dimethyltryptamine (DMT)

0.3 mg/kg Dimethyltryptamine (DMT)

Study Details

Brief summary:

The goal of this fixed order, open-label, dose-escalation study is to investigate the safety and efficacy of specific doses of dimethyltryptamine (DMT) in humans.

Conditions

Major Depressive Disorder

Depression

Study ID

NCT04711915

Start date

Mar 17, 2021

Status verified date

Nov, 2026

Completion date

Dec 1, 2030

Anticipated

Primary completion date

Jul 1, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 21 - 65

Healthy Volunteers: Accepted

Healthy controls inclusion criteria:

  • Medically healthy
  • Psychiatrically healthy

Healthy controls exclusion criteria:

  • Unstable medical conditions
  • Psychiatric illness

Depression inclusion criteria:

  • Medically healthy
  • Diagnosis of major depressive disorder

Depression exclusion criteria:

-Unstable medical conditions

Study Design

Enrollment

10 participants

Anticipated

Allocation

Non randomized

Intervention Model

Crossover

Primary purpose

Other

Interventions and Outcome Measures

Arms

active comparator: 0.1 mg/kg DMT

0.1 mg/kg DMT administered intravenously

active comparator: 0.3 mg/kg DMT

0.3 mg/kg DMT administered intravenously

Interventions

0.1 mg/kg Dimethyltryptamine (DMT)

0.1 mg/kg DMT

0.3 mg/kg Dimethyltryptamine (DMT)

0.3 mg/kg DMT

Primary outcome measure

  • Change in Blood Pressure [ Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration ]
  • Change in Heart Rate [ Time Frame: -60 and -30 minutes before DMT administration; 0, +5, +10, +15, +20, +30, +45, +60, and +120 minutes after DMT administration ]
  • Change in Psychedelic Effects [ Time Frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration ]
  • Change in Anxiety [ Time Frame: -60 minutes before DMT administration; 0, +30, and +60 minutes after DMT administration ]
  • Drug Reinforcing Effects [ Time Frame: +120 minutes after DMT administration ]
  • Overall Tolerability assessed by the VAS [ Time Frame: +120 minutes after DMT administration ]

Central Contacts and Locations

Central contacts

Locations

Biological Studies Unit at the VA Connecticut Healthcare System, Yale School of Medicine

Recruiting

West Haven, Connecticut, United States, 06516

Contacts

Schizophrenia Research Clinic

203-932-5711

Principal Investigator:

Deepak C D'Souza, MD

More Information

Sponsor

Yale University

Last update posted

Nov 18, 2026

Last verified

Nov, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Yale University on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.